Navigation Links
Luminex Corporation To Host Investor Event December 11, 2012
Date:11/27/2012

AUSTIN, Texas, Nov. 27, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) will host an investor event in New York City on Tuesday, December 11, 2012 beginning at 8am ET, as previously announced on its third quarter financial results conference call.  

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Patrick J. Balthrop, president and chief executive officer, and other members of the executive management team will provide insight into the company's long-term strategic plans with a focus on its molecular diagnostic product pipeline.Advanced registration is required and attendance will be limited to those registered. To register, please contact Matthew Scalo, Senior Director of Investor Relations. Breakfast will be served beginning at 7am ET.

The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived on the website using the 'replay' link.

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. We are transforming global healthcare and life-science research through the development, manufacturing, and marketing of proprietary instruments and assays utilizing our xMAP® open-architecture, multi-analyte platform and our MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies that deliver cost-effective and rapid results to clinicians and researchers. Our technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies.  We are meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety.  For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology please visit our website at http://www.luminexcorp.com.Contacts:

Matthew ScaloSr. Director of Investor Relations512-219-8020mscalo@luminexcorp.com 


'/>"/>
SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Luminex Corporation to Present at JP Morgan Healthcare Conference
2. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
3. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
4. Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
5. Luminex Corporation to Present at Jefferies 2012 Global Healthcare Conference
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
8. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
9. Neogen Corporation Announces 2nd Quarter Results Conference Call
10. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
11. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):